Nab-paclitaxel Increases Complete Response Rate in Invasive Breast Cancer

Share this content:

Replacing paclitaxel with nab-paclitaxel, followed by neoadjuvant epirubicin and cyclophosphamide significantly improved the number of patients with primary invasive breast cancer achieving a pathological complete response, a study published in the journal The Lancet Oncology has shown.1

Because nab-paclitaxel has demonstrated significantly increased progression-free survival compared with paclitaxel in metastatic breast cancer, researchers sought to determine whether weekly protein-bound nab-paclitaxel could increase the proportion of patients achieving a pathological complete response compared with weekly solvent-based paclitaxel.

For the phase 3 study, researchers enrolled 1206 women with previously untreated unilateral or bilateral primary invasive breast cancer and randomly assigned them to receive 12 weeks of intravenous nab-paclitaxel 125 mg/m2  to 150 mg/m2 on days 1, 8, and 15 for 4 21-day cycles, or intravenous paclitaxel 80 mg/m2 in the same fashion. All participants then received epirubicin plus cyclophosphamide intravenously on day 1 for 4 21-day cycles, in addition to trastuzumab and pertuzumab if patients had human epidermal growth factor receptor 2 (HER2)-positive tumors.

Results showed that the pathological complete response rate was 38% (95% CI: 35-42) in the nab-paclitaxel group compared with 29% (95% CI: 25-33) in the paclitaxel group (OR, 1.53; 95% CI: 1.20-1.95; P = .00065).

In terms of safety, the incidence of grade 3 or 4 anemia and peripheral sensory neuropathy was significantly higher for nab-paclitaxel than paclitaxel (P = .048 and P < .001, respectively). Serious adverse events occurred in 26% and 21% of the nab-paclitaxel and solvent-based paclitaxel arm, respectively (P = .057). Of note, 3 deaths occurred during the epirubicin and cyclophosphamide regimen in the nab-paclitaxel group compared with 1 death in the paclitaxel group.

“These results might lead to an exchange of the preferred taxane, solvent-based paclitaxel, for nab-paclitaxel in therapy for primary breast cancer,” the authors concluded.


1. Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial [published online ahead of print February 8, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00542-2.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs